Effects of growth hormone-releasing hormone receptor antagonist, MIA-602, in mood disordexs: a potentlal treatment for post-traumatic stress disoxders (PTSD).
Progetto Anxiety and depression have been suggested to increase the risk for post-traumatic stress disorders (PTSD). A link between all these mental illnesses, inflammation and oxidative stress is also well established. On the other hand, anxiety and depressive disorders can also occur, both in the setting of endocrine diseases and as events secondary to the pathogenetic mechanisms of the endocrinopathy. The complexity of the topic and the limited availability of relevant scientific literature make understanding the relationship between the endocrine system and emotional disorders even more complicated. Interestingly, the anxiolytic-antidepressant effect of growth hormone releasing hormone (GHRH) analogs, recently reported by our research group, suggests that GHRH itself may be involved in behavioral control. The powerful anxiolytic and antidepressant-like effects of GHRH analogs are probably related to modulatory effects on the inflammatory, oxidative status and neuroplasticity. The aim of this project will be to confirm the potential beneficial effect of MIA- 602, a recently developed GHRH antagonist, in mood disorders such as PTSD, in both preclinical and clinical studies.